Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)

BACKGROUND: Intratumoral injection of talimogene laherparepvec evokes a cytotoxic immune response. Therefore, the combination of talimogene laherparepvec with trabectedin and nivolumab may have synergistic effects in advanced sarcomas. PATIENTS AND METHODS: This phase 2 trial was conducted from May...

Descripción completa

Detalles Bibliográficos
Autores principales: Chawla, Sant P., Tellez, Walter Andree, Chomoyan, Hripsime, Valencia, Chrysler, Ahari, Amir, Omelchenko, Nadezhda, Makrievski, Stefan, Brigham, Don A., Chua-Alcala, Victoria, Quon, Doris, Moradkhani, Ania, Gordon, Erlinda M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206273/
https://www.ncbi.nlm.nih.gov/pubmed/37234994
http://dx.doi.org/10.3389/fonc.2023.1116937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206273/
https://www.ncbi.nlm.nih.gov/pubmed/37234994
http://dx.doi.org/10.3389/fonc.2023.1116937

Ejemplares similares